Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
We examined the impact of statins on Yes-associated Protein (YAP) localization, phosphorylation and transcriptional activity in human and mouse pancreatic ductal adenocarcinoma (PDAC) cells. Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Statins also prevented YAP nuclear import and expression of CTGF and CYR61 stimulated by the mitogenic combination of insulin and neurotensin in dense culture of these PDAC cells. Cerivastatin, simvastatin, atorvastatin and fluvastatin also inhibited colony formation by PANC-1 and MiaPaCa-2 cells in a dose-dependent manner. In contrast, the hydrophilic statin pravastatin did not exert any inhibitory effect even at a high concentration (10 μM). Mechanistically, cerivastatin did not alter the phosphorylation of YAP at Ser127 in either PANC-1 or MiaPaCa-2 cells incubated without or with neurotensin and insulin but blunted the assembly of actin stress fiber in these cells. We extended these findings with human PDAC cells using primary KC and KPC cells, (expressing KrasG12D or both KrasG12D and mutant p53, respectively) isolated from KC or KPC mice. Using cultures of these murine cells, we show that lipophilic statins induced striking YAP translocation from the nucleus to the cytoplasm, inhibited the expression of Ctgf, Cyr61 and Birc5 and profoundly inhibited colony formation of these cells. Administration of simvastatin to KC mice subjected to diet-induced obesity prevented early pancreatic acini depletion and PanIN formation. Collectively, our results show that lipophilic statins restrain YAP activity and proliferation in pancreatic cancer cell models in vitro and attenuates early lesions leading to PDAC in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Statins, including simvastatin, have also shown antifibrotic potential in preclinical studies by promoting YAP cytoplasmic retention and inactivation, offering opportunities for drug repurposing (144, 145).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [144]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · cited 2×
“It has been anticipated that PDAC will be the 3 leading cause of cancer-related mortalities in the USA by the end of 2018 [1] and projected to become the 2 leading cause of cancer-related mortality in the USA before 2030 [2].”
BackgroundEtienne-Manneville, S., & Hall, A. (2002) · Nature · doi:10.1038/nature01148 · Cited by 4,201 · cited 1×
“Rho plays a critical role in F-actin organization and in the assembly of actin stress fibers in a variety of cell types [70].”
BackgroundCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · cited 1×
“Virtually all PanIN lesions and invasive PDAC entail activating mutations in the KRAS oncogene, which represent an initiating event in the development of the disease [5, 6].”
BackgroundA pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371 · cited 1×
“We used the Pathology Atlas [62] based on the integration of publicly available data from The Cancer Genome Atlas (TCGA) and data generated within the framework of the Human Protein Atlas (HPA) and analyzed transcriptomics and survival in 176 PDAC patients [62].”
MethodPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“PDAC arises from precursor lesions, the most common of which are pancreatic intraepithelial neoplasia (PanIN) [3, 4].”
BackgroundPancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 1×
“Virtually all PanIN lesions and invasive PDAC entail activating mutations in the KRAS oncogene, which represent an initiating event in the development of the disease [5, 6].”
BackgroundSelf-citationYAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970 · cited 1×
“The highly conserved transcriptional co-activator YAP and its paralog TAZ, originally identified in Drosophila, are emerging as potent oncogenes for a variety of cell types [20, 64].”
BackgroundMechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 3×
“The transfer of the geranylgeranyl moiety of GG-PP to a COOH-terminal cysteine of Rho GTPases is critical for their membrane localization and function in signal transduction through actin remodeling [12].”
BackgroundGenetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Research works printed but not linked: 2
- Yang S, Zhang L, Purohit V, Shukla SK, Chen X, Yu F, et al Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3 2015 10.18632/oncotarget.5935 26440309 PMC4742158 · DOI · Paper page
- Hamada T, Khalaf N, Yuan C, Morales-Oyarvide V, Babic A, Nowak JA, et al Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018; 16(8): 1300– 6.e3. 10.1016/j.cgh.2018.02.022 29474971 PMC6056316 · DOI · Paper page
Cited by
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Vell, M. S., Loomba, R. S., Krishnan, A., Wangensteen, K. J., Trebicka, J., Creasy, K. T., Trautwein, C., Scorletti, E., Seeling, K. S., Hehl, L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.20222 · Cited by 137
The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis
Kovar, H., Bierbaumer, L., & Radic-Sarikas, B. (2020) · Cells · doi:10.3390/cells9040972 · Cited by 127
Mokhtari, R. B., Ashayeri, N., Baghaie, L., Sambi, M., Satari, K., Baluch, N., Bosykh, D. A., Szewczuk, M. R., & Chakraborty, S. (2023) · Cancers · doi:10.3390/cancers15133468 · Cited by 100
Ortega, Á., Vera, I., Díaz, M. I., Navarro, C., Rojas, M., Torres, W., Parra, H., Salazar, J. J., Sanctis, J. B. D., & Bermúdez, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010430 · Cited by 95
Pleiotropic use of Statins as non-lipid-lowering drugs
Zhang, Q., Dong, J., & Yu, Z. Y. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.42965 · Cited by 86
“Statins regulate YAP protein entry into the nucleus by influencing the conformation of cytoskeleton [61, 62].”
BackgroundScreening for YAP inhibitors identifies statins as modulators of fibrosis
Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0296oc · Cited by 72
“Cerivastatin and simvastatin have been shown to induce S127-YAP phosphorylation in MDA-MB-231 breast cancer cells (19, 20), but not in human pancreatic cancer cells (55).”
BackgroundYAP in pancreatic cancer: oncogenic role and therapeutic strategy
Mao, W., Mai, J., Peng, H., Wan, J., & Sun, T. (2020) · Theranostics · doi:10.7150/thno.53438 · Cited by 60
“Preclinical studies have shown that statins delay the progression of pancreatic lesions to carcinoma or prevent the initial stages of PDAC in KrasG12D mice [116, 117].”
BackgroundChang, H.-H., & Eibl, G. (2019) · Cells · doi:10.3390/cells8070673 · Cited by 51
“In our own study using a genetically engineered mouse model of pancreatic cancer promoted by diet-induced obesity, we found that oral administration of simvastatin attenuated early pancreatic neoplastic progression [148], which was accompanied by a marked reduction of inflammation in the VAT (unpublished; Figure 1).”
BackgroundSelf-citationRegulation of Hippo signaling pathway in cancer: A MicroRNA perspective
Samji, P., Rajendran, M. K., Warrier, V. P., Ganesh, A., & Karunagaran, D. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109858 · Cited by 42
Angeli, S., Neophytou, C., Kalli, M., Stylianopoulos, T., & Mpekris, F. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1564626 · Cited by 41
Kim, D., Ahn, H. S., & Kim, H. J. (2021) · International Journal of Cancer · doi:10.1002/ijc.33869 · Cited by 40
“Lipophilic statins can penetrate the cell plasma membrane more easily than hydrophilic statins, and the cellular penetration may be associated with inhibition of cell growth.(59) Lastly, we excluded patients who had died or had received a new cancer diagnosis within 1 year during the follow-up period to prevent other…”
BackgroundLiu, X., Wang, Y., Chen, B., Chan, W. N., Mui, C. W., Cheung, A. H. K., Zhang, J., Wong, K. Y., Yu, J. Q., Kang, W., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102512 · Cited by 36
Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression
Zhou, R., Wang, H., Zhang, G., Liu, Y., Liu, X., Li, Z., Shi, G., Yuan, J., Qu, C., Li, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64426-7 · Cited by 34
“Some repurposed drugs, such as the tyrosine kinase inhibitor dasatinib 15 and cholesterol-lowering statins 16 , have been found to indirectly and nonspeci fi cally inhibit YAP/TAZ, but with limited ef fi cacy 17 .”
Self-citationRozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30
“In many cell types, changes in actin cytoskeletal organization play a critical role in YAP/TAZ activation [112], including in PDAC cells [157].”
BackgroundSelf-citationQin, C. Y., Zhao, B., Wang, Y., Li, Z., Li, T., Zhao, Y., Wang, W., & Zhao, Y. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12488 · Cited by 32
“Rescue experiments focusing on the miR-31-5p/LATS2 pathway at the protein level showed that LATS2 could reverse the effects of miR-31-5p on the Hippo pathway and its downstream targets, such as BIRC5 (Hao et al., 2019) (Figure 4i,j).”
Background(2025) · doi:10.3389/fimmu.2025.1670213 · Cited by 29
“Statins, including simvastatin, have also shown anti fi brotic potential in preclinical studies by promoting YAP cytoplasmic retention and inactivation, offering opportunities for drug repurposing (144, 145).”
Self-citationHoward, A., Bojko, J., Flynn, B. P., Bowen, S., Jungwirth, U., & Walko, G. (2022) · Experimental Dermatology · doi:10.1111/exd.14655 · Cited by 29
Wu, Z., Wang, C., Chen, Y., Sun, Z., & Yan, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s225602 · Cited by 26
Drivers of Gene Expression Dysregulation in Pancreatic Cancer
Venkat, S., Alahmari, A. A., & Feigin, M. E. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.008 · Cited by 26
Qi, C., Min, P., Wang, Q., Wang, Y., Song, Y., Zhang, Y., Bibi, M., & Du, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9955717 · Cited by 22
Sinnett‐Smith, J. W., Anwar, T., Reed, E. F., Teper, Y., Eibl, G., & Rozengurt, E. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0964 · Cited by 18
Self-citationWang, L., Tang, D.-R., Wu, T., & Sun, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.673904 · Cited by 17
Benhammou, J. N., Qiao, B., Ko, A., Sinnett‐Smith, J. W., Pisegna, J. R., & Rozengurt, E. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00089.2023 · Cited by 17
Self-citation(2023) · PubMed Central · Cited by 15
Saito, Y., Xiao, Y. Q., Yao, J., Li, Y., Liu, W., Yuzhalin, A. E., Shyu, Y.-M., Li, H., Yuan, X., Li, P., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00720-w · Cited by 13
“Although no Yap1-speci fi c inhibitor has been approved for treating cancer patients, common Statins can target the mevalonate pathway to block Yap1 nuclear localization and Yap1 target gene expression in PDAC cells in vitro and in vivo 53 .”
Self-citationAssociation between statins exposure and risk of skin cancer: an updated meta‐analysis
Wang, D., Dai, S., Lou, D., Wang, T., Wang, S., & Zheng, Z. (2023) · International Journal of Dermatology · doi:10.1111/ijd.16816 · Cited by 12
Ma, W., Wei, S., Li, Q., Zeng, J., Xiao, W., Zhou, C., Yoneda, K. Y., Zeki, A. A., & Li, T. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0458 · Cited by 12
Bianchi, F., Sommariva, M., Cornaghi, L., Denti, L., Nava, A., Arnaboldi, F., Moscheni, C., & Gagliano, N. (2022) · Cells · doi:10.3390/cells11081318 · Cited by 12
“Indeed, lipophilic statins were recently reported to restrain YAP activity and proliferation in pancreatic cancer cell models in vitro and to attenuate early lesions leading to PDAC in vivo [34].”
BackgroundTeper, Y., Ye, L., Waldron, R. T., Lugea, A., Sun, X., Sinnett-Smith, J., Hines, O. J., Pandol, S. J., Rozengurt, E., & Eibl, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-43498-9 · Cited by 10
“As alpha smooth muscle actin-positive pancreatic stellate cells express YAP and TAZ in human and murine PDAC 27 , an inhibitory action of metformin and statins on YAP/TAZ activity, as seen in our study, can plausibly disrupt the pro-fibroinflammatory role of pancreatic stellate cells and the pro-tumorigenic crosstalk…”
InfluentialSelf-citationHao, F. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02826-7 · Cited by 10
“Our preliminary experiments demonstrated that well-tolerated cholesterol-lowering drugs of statin family and metformin had anti-tumor effects and could inhibit tumor growth via regulation of YAP, which repurposed the known drugs as YAP/TAZ inhibitors [46].”
BackgroundSelf-citationIannelli, F., Lombardi, R., Costantini, S., Roca, M. S., Addi, L., Bruzzese, F., Gennaro, E. D., Budillon, A., & Pucci, B. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03573-1 · Cited by 10
“However, some studies have suggested that the effect of statins is independent of MST1/2 and LATS1/2 activity [38, 39], whereas others have described a significant induction of LATS1 expression upon statin treatment [40, 41].”
Tamburrino, D., Guarneri, G., Pagnanelli, M., Crippa, S., Partelli, S., Belfiori, G., Capurso, G., & Falconi, M. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09097-y · Cited by 10
Recent insight into the role and therapeutic potential of YAP/TAZ in gastrointestinal cancers
Wang, Y., Chen, H., Yu, J. Q., Kang, W., & To, K. F. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188787 · Cited by 8
PNLIPRP1 Hypermethylation in Exocrine Pancreas Links Type 2 Diabetes and Cholesterol Metabolism
Maurin, L., Marselli, L., Boissel, M., Ning, L., Boutry, R., Fernandes, J., Suleiman, M., Luca, C. D., Leloire, A., Pascat, V., et al. (2024) · Diabetes · doi:10.2337/db24-0215 · Cited by 5
Statin Type and Cancer Outcomes in Patients with Diabetes Type 2 and Solid Tumors
Ceacareanu, A. C., Jolly, S. D., Nimako, G. K., & Wintrob, Z. A. P. (2021) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_21_3 · Cited by 5
“Several clinical and preclinical studies have found that lipophilic statins appear to possess superior anticancer properties against breast, esophageal, and pancreatic cancers.[16-18] In contrast, hydrophilic statins appear to be superior to lipophilic statins in the case of prostate cancer.”
BackgroundZhang, Y., Ren, Y., Li, X., Li, M., Fu, M., Zhou, W., Yu, Y., & Xiong, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132473 · Cited by 5
Mechanisms of Hippo pathway in the pancreatic cancer
Xie, R., & Chen, R. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000041 · Cited by 4
Benhammou, J. N., Sinnett-Smith, J., Pisegna, J. R., & Rozengurt, E. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.07.017 · Cited by 4
Self-citationAko, S., Teper, Y., Ye, L., Sinnett-Smith, J., Hines, O. J., Rozengurt, E., & Eibl, G. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.04.012 · Cited by 3
“35 Since statins are known inhibitors of YAP/TAZ in several cell types, 20,36 it is conceivable that the inhibitory effect of lipophilic statins on inflammatory cytokine production by macrophages is mediated by inhibiting YAP and TAZ downstream of Rho GTPases and actin.”
InfluentialSelf-citationPereira, M., Glogova, A., Haagsma, J., Stewart, J., Shepherd, T. G., & Petrik, J. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01307-x · Cited by 3
“Previous reports have confirmed statin treatment induced accumulation of HMGCR instead of its degradation, coupled with decreased transcription and mRNA levels of HMGCR [43], with YAP expression being significantly downregulated in human pancreatic cancer cells following statin treatment [44].”
BackgroundWaldron, R. T., Lugea, A., Chang, H.-H., Su, H., Quiros, C., Lewis, M. S., Che, M., Ramanujan, V. K., Rozengurt, E., Eibl, G., et al. (2024) · Cancers · doi:10.3390/cancers16081593 · Cited by 3
“This supports the beneficial effect of statin-based treatments, selectively targeting this pathway [69] as a precision medicine approach to PDAC.”
BackgroundSelf-citationObesity and cancers of the liver, gallbladder, and pancreas
Sarna, M. J., & Giorgi, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90965-5.00002-7 · Cited by 3
Advances towards potential cancer therapeutics targeting Hippo signaling
Zhu, R., Jiao, Z., & Yu, F. (2024) · Biochemical Society Transactions · doi:10.1042/bst20240244 · Cited by 3
YAP1 signaling and cancer: molecular pathways reveal novel targeting opportunities
Wu, J., Chen, B., Xie, F., Hu, J., Liang, M., Lyu, Y., Yu, P., Feng, T., Tian, R., & Kang, W. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2638749 · Cited by 2
“Repurposed drugs, including the tyrosine kinase inhibitor dasatinib and cholesterol-lowering statins, have been shown to indirectly suppress YAP1/TAZ activity [129,130]; however, their effects are nonspecific and clinical efficacy remains limited.”
[Nucleus translocation of membrane/cytoplasm proteins in tumor cells].
Zhu, Z., Tan, J. S., & Deng, H. (2019) · PubMed · doi:10.3785/j.issn.1008-9292.2019.06.13 · Cited by 2
Chahardehi, A. M., Naseri, A., Mali, E., Ziaei, L., Moradi, F., Teimourpour, F., Tajik, L., Motedayyen, H., Meigoli, M. S. S., Nasiri, R., et al. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.08.016 · Cited by 1
“Additionally, due to their unique properties, lipo-philic statins might further affect YAP through their regulatory effects on RhoGTPases, which are key regulators of cell migration and invasion, thereby providing an additional mechanism for statins to target cancer cells (Hao et al., 2019).”
Statin repurposing in gastrointestinal cancer: from metabolic reprogramming to immunoregulation
Xu, M., Yu, C. M., Chung, H. K. H., & Zhou, J. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf187 · Cited by 1
The MST4–14-3-3ζ complex promotes pancreatic cancer by activating YAP
Tian, L., Zhao, Z., Ding, S., Li, M. C., Han, Y., Zhu, C., Pan, Y. T., Wang, X. L., Kang, W., An, L., et al. (2026) · Biology Direct · doi:10.1186/s13062-026-00784-6 · Cited by 1
Labrecque, C. L., Ko, A., Qiao, B., Pan, C., Nandakumar, R., Chowdhury, K., Venkatesan, N., Du, X., Cai, B., Pellegrini, M. A., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001015 · Cited by 1
“[5,24,44] The HSC-HCC upregulation of YAP-effectors genes in our human snRNAseq data suggests that YAP and its downstream effectors are critical to HCC and its microenvironment, beyond their role in cirrhosis.”
Self-citationBurr, N. E. (2020) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Sinnett‐Smith, J. W., Anwar, T., Reed, E. F., Teper, Y., Eibl, G., & Rozengurt, E. (2023) · doi:10.1158/1535-7163.c.6543589
Self-citationBADGER: biologically-aware interpretable differential gene expression ranking model
Kim, H., Gim, M., Baek, S., Park, S., Kim, S., & Kang, J. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbaf029
“Hao et al. (2019) demonstrates that cerivastatin plays a significant role in pancreatic cancer by modulating the localization and activity of YAP, inhibiting important gene expressions related to cancer progression, and impacting cancer cell proliferation.”
Pereira, M., Glogova, A., Haagsma, J., Stewart, J., Shepherd, T. G., & Petrik, J. (2024) · Figshare · doi:10.6084/m9.figshare.24597749
Pereira, M., Glogova, A., Haagsma, J., Stewart, J., Shepherd, T. G., & Petrik, J. (2023) · Figshare · doi:10.6084/m9.figshare.24597541
Pereira, M., Glogova, A., Haagsma, J., Stewart, J., Shepherd, T. G., & Petrik, J. (2024) · Figshare · doi:10.6084/m9.figshare.26642686
Mshary, G. S. (2025) · Kufa Journal of Pharmaceutical Sciences
Metadata
- Authors
- Hao, F., Xu, Q., Wang, J., Yu, S., Chang, H.-H., Sinnett-Smith, J., Eibl, G., & Rozengurt, E.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Rozengurt, Enrique
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-05-17
- Volume
- 14
- Issue
- 5
- Pages
- e0216603
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6524808
- OpenAlex
- W2945457209
- Cited by
- 55
- References
- 77
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 11 · 2023: 10 · 2022: 9 · 2021: 6 · 2020: 9 · 2019: 2
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, public-domain)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100405, P30DK041301)
- National Cancer Institute (P01CA163200)
- U.S. Department of Veterans Affairs (I01BX003801)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- lipophilic statins, YAP, pancreatic ductal adenocarcinoma, cerivastatin, simvastatin, YAP nuclear localization, YAP phosphorylation, connective tissue growth factor, CYR61, survivin, colony formation, stress fibers, KRAS G12D, KPC mice, pancreatic intraepithelial neoplasia, diet-induced obesity
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Nucleus, Colony-Forming Units Assay, Humans, Mutation, Pancreatic Neoplasms, Phosphorylation, Transcription Factors, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Hydroxymethylglutaryl-CoA Reductase Inhibitors, Protein Transport, Carcinoma, Pancreatic Ductal, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.